Phage lysin biosensor detection of MRSA: point of care prototype: PROMPT-Plus

MRSA被广泛认为是所谓的“超级细菌”之一，因为它是许多医疗保健相关感染事件的原因，并且它对许多常见的抗生素具有耐药性。因此，能够快速检测和测量MRSA是非常重要的，特别是当人们通过事故和紧急路线入院时，以避免任何感染的机会。TSB在2011-2012年资助的PROMPT可行性项目成功地证明了一种新型的基于生物传感器的系统可以在现场条件下特异性地检测MRSA。这一成功导致了PROMPT-Plus项目，该项目旨在将生物传感器系统进一步开发为完全可操作的护理点原型，并将在NHS信任实验室进行测试。生物传感器系统的概念是由ELISHA系统有限公司在食品和环境研究机构（FERA）的支持下构思的，未来将由英国生物细胞国际有限公司（BBI）商业化。

MRSA is widely recognised as one of the so called 'superbugs' as it is responsible for many incidents of healthcare related infections and it is also resistant to many of the common antibiotics available. It is therefore very important to be able to rapidly detect and measure MRSA, especially when people are admitted to hospital through the accident & emergency route, so as to avoid any chance of infection. The PROMPT feasibility project funded in 2011-2012 by the TSB successfully demonstrated a new type of biosensor based system could specifically detect MRSA under field conditions. This success has led to the PROMPT-Plus project that aims to further develop the biosensor system to fully operational point-of-care prototypes that will be tested in NHS trust laboratories. The concept for the biosensor system was conceived by ELISHA Systems Ltd with support from the Food and Environment Research Agency (FERA) and will be commercialised in the future by British Biocell International Ltd (BBI)